Table 1 The relationship between CCL5 expression and CRC clinicopathological features
| Â | No. of cases | Low | Medium | High | x2 value | P-value |
|---|---|---|---|---|---|---|
Frequency | 195 (100%) | 65 (33.3%) | 92 (47.2%) | 38 (19.5%) | Â | Â |
Age | ||||||
  < 60 years | 96 (49.2%) | 33 (34.4%) | 40 (41.7%) | 23 (24.0%) | 3.219 | 0.200 |
  >  = 60 years | 99 (50.8%) | 32 (32.3%) | 52 (52.5%) | 15 (15.2%) |  |  |
Gender | ||||||
 Male | 119 (61.0%) | 43 (36.1%) | 50 (42.0%) | 26 (21.8%) | 3.317 | 0.190 |
 Female | 76 (39.0%) | 22 (28.9%) | 42 (55.3%) | 12 (15.8%) |  |  |
Position | ||||||
 Colon | 128 (65.6%) | 41 (32.0%) | 61 (47.7%) | 26 (20.3%) | 2.471 | 0.650 |
 Rectum | 58 (29.7%) | 20 (34.5) | 26 (44.8%) | 12 (20.7%) |  |  |
 Colorectum | 9 (4.6%) | 4 (44.4%) | 5 (55.6%) | 0 (0.0%) |  |  |
Tumor size(maximum diameter) | ||||||
  < 5 cm | 99 (51.0%) | 30 (30.3%) | 52 (52.5%) | 17 (17.2%) | 2.155 | 0.340 |
  >  = 5 cm | 95 (49.0%) | 34 (35.8%) | 40 (42.1%) | 21 (22.1%) |  |  |
Histology | ||||||
 Poor | 22 (11.3%) | 6 (27.3%) | 13 (59.1%) | 3 (13.6%) | 1.505 | 0.826 |
 Moderate | 155 (79.5%) | 53 (34.2%) | 71 (45.8%) | 31 (20.0%) |  |  |
 Well | 18 (9.2%) | 6 (33.3%) | 8 (44.4%) | 4 (22.2%) |  |  |
T stage | ||||||
 Tis | 2 (1.0%) | 2 (100.0%) | 0 (0.0%) | 0 (0.0%) | 22.460 | 0.004 |
 T1 | 4 (2.1%) | 3 (75.0%) | 1 (25.0%) | 0 (0.0%) |  |  |
 T2 | 21 (10.8%) | 6 (28.6%) | 11 (52.4%) | 4 (19.0%) |  |  |
 T3 | 123 (63.1%) | 47 (38.2%) | 59 (48.0%) | 17 (13.8%) |  |  |
 T4 | 45 (23.1%) | 7 (15.6%) | 21 (46.7%) | 17 (37.8%) |  |  |
Tumor budding | ||||||
 Bd1 | 83 (42.6%) | 53 (63.9%) | 26 (31.3%) | 4 (4.8%) | 84.614 |  < 0.001 |
 Bd2 | 72 (36.9%) | 9 (12.5%) | 50 (69.4%) | 13 (18.1%) |  |  |
 Bd3 | 40 (20.5%) | 3 (7.5%) | 16 (40.0%) | 21 (52.5%) |  |  |
Lymphatic metastasis | ||||||
 Negative | 107 (54.9%) | 46 (43.0%) | 46 (43.0%) | 15 (14.0%) | 11.154 | 0.004 |
 Positive | 88 (45.1%) | 19 (21.6%) | 46 (52.3%) | 23 (26.1%) |  |  |
Tumor deposits | ||||||
 Absent | 171 (87.7%) | 61 (35.7%) | 82 (48.0%) | 28 (16.4%) | 9.366 | 0.009 |
 Present | 24 (12.3%) | 4 (16.7%) | 10 (41.7%) | 10 (41.7%) |  |  |
Mucinous component | ||||||
 Absent | 162 (83.1%) | 53 (32.7%) | 77 (47.5%) | 32 (19.8%) | 0.169 | 0.919 |
 Present | 33 (16.9%) | 12 (36.4%) | 15 (45.5%) | 6 (18.2%) |  |  |
Distant metastasis | ||||||
 Negative | 182 (93.3%) | 63 (34.6%) | 83 (45.6%) | 36 (19.8%) | 2.902 | 0.234 |
 Positive | 13 (6.7%) | 2 (15.4%) | 9 (69.2%) | 2 (15.4%) |  |  |
Microstatellite instability | ||||||
 MSS | 161 (82.6%) | 53 (32.9%) | 74 (46.0%) | 34 (21.1%) | 4.754 | 0.314 |
 MSI-L | 11 (5.6%) | 6 (54.5%) | 5 (45.5%) | 0 (0.0%) |  |  |
 MSI-H | 23 (11.8%) | 6 (26.1%) | 13 (56.5%) | 4 (17.4%) |  |  |
Neoadjuvant chemotherapy | ||||||
 Negative | 186 (95.4%) | 61 (32.8%) | 90 (48.4%) | 35 (18.8%) | 2.523 | 0.283 |
 Positive | 9 (4.6%) | 4 (44.4%) | 2 (22.2%) | 3 (33.3%) |  |  |
TNM stage | ||||||
 0 | 2 (1.0%) | 2(100.0%) | 0 (0.0%) | 0 (0.0%) | 41.890 |  < 0.001 |
 I | 18 (9.2%) | 8 (44.4%) | 7 (38.9%) | 3 (16.7%) |  |  |
 IIA | 12 (6.2%) | 32 (45.7%) | 30 (42.9%) | 8 (11.4%) |  |  |
 IIB | 70 (35.9%) | 2 (22.2%) | 4 (44.4%) | 3 (33.3%) |  |  |
 IIIA | 4 (2.1%) | 1 (25.0%) | 2 (50.0%) | 1 (25.0%) |  |  |
 IIIB | 56 (28.7%) | 15 (26.8%) | 34 (60.7%) | 7 (12.5%) |  |  |
 IIIC | 24 (12.3%) | 3 (12.5%) | 7 (29.2%) | 14 (58.3%) |  |  |
 IV | 12 (6.2%) | 2 (16.7%) | 8 (66.7%) | 2 (16.7%) |  |  |